Evidence map›Paper›PMID 34012272›Full record

ArticleOncoTargets and therapy2021

Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report.

Qian Li, Wei Liu, Kai Li, Yifu Tian, Huan Li

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Qian LiLung Hospital, Changsha Central Hospital, University of South China, Changsha, Hunan Province, People's Republic of China.
Wei LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province, People's Republic of China.
Kai LiDepartment of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan Province, People's Republic of China.
Yifu TianDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan Province, People's Republic of China.
Huan LiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province, People's Republic of China.
Central South University · CNChangsha Central Hospital · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-Hodgkin lymphoma can disseminate to the central nervous system at initiation of treatment for systemic lymphoma or spread during the relapse of systematic lymphoma with CNS involvement, which is defined as secondary central nervous system lymphoma (SCNSL). The incidence of SCNSL depends on the pathological type of lymphoma and is especially high in aggressive lymphoma. SCNSL has a poor prognosis because of the lack of effective treatment regimens. This article presents a rare case of SCNSL; an individualized treatment regimen was designed according to the genetic analyses of the patient tumor and included a Bruton's tyrosine kinase (BTK) inhibitor. After six cycles of treatment and another two cycles of rituximab, most lesions lost their metabolic activity. However, in the final stage of treatment, our patient unfortunately suffered from respiratory failure, which revealed that we should pay attention to

Indexed as

diffuse large B cell lymphomaibrutinibindividualized therapyPneumocystis jirovecii pneumoniasecondary central nervous system lymphoma

Identifiers

PMID34012272
PMCPMC8128509
OpenAlexW3163227012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.